Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AssigneeApplied Research Systems ARS Holding N.V.
InventorsTerry Strom, Wlodzimierz Maslinski
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds, such as proteins, peptides and organic compounds, capable of blocking or inhibiting the binding interaction of Raf-1 or 14-3-3 proteins to the β chain of IL-2, and pharmaceutical compositions containing such compounds. In vitro assays for isolating, identifying and characterizing such compound capable of inhibiting interaction of Raf-1 or 14-3-3 proteins to IL-2β are also provided.
Claims2
A compound capable of disrupting the binding of Raf-1 protein and 14-3-3 to IL-2Rβ and selected from the group consisting of a peptide having the amino acid sequence corresponding to residues 370 to 396 of SEQ ID NO:2, an analog of said peptide where one amino acid residue of residues 370 to 396 of SEQ ID NO:2 is replaced with a different amino acid residue or deleted, and a chemical derivative of said peptide which enhances the peptide's permeability across the cell membrane or facilitates the transport of the Peptide through the membrane into the cytoplasm, wherein said compound is not a full length human IL-2Rβ chain.
Dependencies are inferred from the claim text.